

Alberto N Peñón

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/933727/publications.pdf>

Version: 2024-02-01

24
papers

324
citations

1040056

9
h-index

1199594

12
g-index

24
all docs

24
docs citations

24
times ranked

506
citing authors

#	ARTICLE	IF	CITATIONS
1	Alternatively Activated Macrophages in Types 1 and 2 Diabetes. Mediators of Inflammation, 2012, 2012, 1-10.	3.0	81
2	Reducing surgical site infections in low-income and middle-income countries (FALCON): a pragmatic, multicentre, stratified, randomised controlled trial. Lancet, The, 2021, 398, 1687-1699.	13.7	49
3	Ischemia/Reperfusion Injury: Pathophysiology, Current Clinical Management, and Potential Preventive Approaches. Mediators of Inflammation, 2020, 2020, 1-13.	3.0	37
4	Immunoregulation by <i>Taenia crassiceps</i> and Its Antigens. BioMed Research International, 2013, 2013, 1-13.	1.9	31
5	Tocilizumab reduces COVID-19 mortality and pathology in a dose and timing-dependent fashion: a multi-centric study. Scientific Reports, 2021, 11, 19728.	3.3	27
6	Regulation of immunity by <i>Taeniids</i> : lessons from animal models and <i>in vitro</i> studies. Parasite Immunology, 2016, 38, 124-135.	1.5	25
7	Helminth Products Potently Modulate Experimental Autoimmune Encephalomyelitis by Downregulating Neuroinflammation and Promoting a Suppressive Microenvironment. Mediators of Inflammation, 2017, 2017, 1-16.	3.0	19
8	Intranasal Methylprednisolone Effectively Reduces Neuroinflammation in Mice With Experimental Autoimmune Encephalitis. Journal of Neuro pathology and Experimental Neurology, 2020, 79, 226-237.	1.7	19
9	Nanoparticle-Based Devices in the Control of Antibiotic Resistant Bacteria. Frontiers in Microbiology, 2020, 11, 563821.	3.5	19
10	Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients. BioMed Research International, 2021, 2021, 1-12.	1.9	5
11	Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments. Current Medicinal Chemistry, 2016, 23, 1152-1170.	2.4	5
12	Neuro-Immune-Endocrine Interactions in Multiple Sclerosis. Advances in Neuroimmune Biology, 2018, 7, 55-65.	0.7	3
13	Calculadora de riesgo de progresi3n a hospitalizaci3n por COVID-19, enfermedad cr3tica y muerte. Estudio retrospectivo observacional.. , 2022, 3, 1-15.		3
14	Lophomoniasis associates with chronic immune compromise and respiratory coinfections: a case report.. , 2020, 1, 1-10.		1
15	The five axes of COVID-19 treatment: attacking the disease from several angles.. , 2021, 2, 1-14.		0
16	Enzymes at a glance. , 2021, 2, 1-18.		0
17	Estrategia de vacunaci3n en M3xico y diversidad de vacunas.. , 2021, 2, 1-11.		0
18	A brief history of vaccines and an overview of their benefits.. , 2021, 2, 1-6.		0

#	ARTICLE	IF	CITATIONS
19	PROPERTIES AND MECHANISMS OF ACTION OF NON-REPLICATIVE VIRAL VECTORS, INACTIVATED VIRUSES, RNA AND DNA VACCINES. , 2021, 2, 1-12.		0
20	Diagnostic workflow for small intestine diverticulitis: case series and systematic review.. , 2020, 1, 1-17.		0
21	Inflammatory damage during both shock wave and intracorporeal laser lithotripsy. , 2020, 1, 1-15.		0
22	The five axes of COVID-19 treatment: attacking the disease from several angles.. , 2020, 2, 1-32.		0
23	Inmunosupresión vs. Inmunorregulación en COVID-19. PÁGINA Boletín Científico De Ciencias Básicas E Ingenierías Del ICBI, 2022, 9, 146-152.	0.0	0
24	Fomento de la lactancia materna: evaluación de una estrategia multidisciplinaria.. , 2022, 3, 1-25.		0